Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 2, 2009, Pages 167-174

  Kim, Jahye ^a   Ohtani, Hisakazu ^b   Tsujimoto, Masayuki ^a   Sawada, Yasufumi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug interaction; Fluoroquinolone; GABAA inhibition; NSAIDs; Pharmacodynamic modeling

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 6 FLUORO 1 METHYL 4 OXO 7 (1 PIPERAZINYL) 4H 1,3 THIAZETO[3,2 A]QUINOLINE 3 CARBOXYLIC ACID; CIPROFLOXACIN; DICLOFENAC; ENOXACIN; FELBINAC; FLEROXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; LORNOXICAM; LOXOPROFEN; MUSCIMOL; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TOSUFLOXACIN; ZALTOPROFEN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG BRAIN LEVEL; DRUG POTENTIATION; IN VITRO STUDY; INHIBITION KINETICS; MALE; MATHEMATICAL COMPUTING; MAXIMUM PLASMA CONCENTRATION; MEDICAL LITERATURE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; RECEPTOR OCCUPANCY; RISK ASSESSMENT; SYNAPTIC MEMBRANE;

EID: 67649360010     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.167     Document Type: Article

References (41)

1. Owens, R. C. Jr and Ambrose, P. G.: Antimicrobial safety: focus on fluoroquinolones. Clin. Infect. Dis., 41 Suppl 2: S144-S157 (2005).
2. Lipsky, B. A. and Baker, C. A.: Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis., 28: 352-364 (1999).
3. Akahane, K., Sekiguchi, M., Une, T. and Osada, Y.: Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob. Agents Chemother., 33: 1704-1708 (1989).
4. Squires, R. F. and Saederup, E.: Indomethacin/ibuprofen-like anti-inflammatory agents selectively potentiate the gamma-aminobutyric acid-antagonistic effects of several norfloxacin-like quinolone antibacterial agents on. Mol. Pharmacol., 43: 795-800 (1993).
5. Shirasaki, T., Harata, N., Nakaye, T. and Akaike, N.: Interaction of various non-steroidal anti-inflammatories and quinolone antimicrobials on GABA response in rat dissociated hippocampal pyramidal neurons. Brain Res., 562: 329-331 (1991).
6. Kita, H., Matsuo, H., Takanaga, H., Kawakami, J., Yamamoto, K., Iga, T., Naito, M., Tsuruo, T., Asanuma, A., Yanagisawa, K. and Sawada, Y.: In vivo and in vitro toxicodynamic analyses of new quinolone-and nonsteroidal anti-inflammatory drug-induced effects on the central nervous system. Antimicrob. Agents Chemother., 43: 1091-1097 (1999).
7. Matsuo, H., Ryu, M., Nagata, A., Uchida, T., Kawakami, J. I., Yamamoto, K., Iga, T. and Sawada, Y.: Neurotoxicodynamics of the interaction between ciprofloxacin and foscarnet in mice. Antimicrob. Agents Chemother., 42: 691-694 (1998).
8. Enna, S. J., Wood, J. H. and Snyder, S. H.: Gamma-Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay. J. Neurochem., 28: 1121-1124 (1977).
9. Yamaoka, K., Tanigawara, Y., Nakagawa, T. and Uno, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn., 4: 879-885 (1981).
10. Hori, S., Kizu, J. and Kawamura. M.: Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. J. Infect. Chemother., 9: 314-320 (2003).
11. Cole, L. M., Lawrence, L. J. and Casida, J. E.: Similar properties of [35S]t-butylbicyclophosphorothionate receptor and coupled components of the GABA receptor-ionophore complex in brains of human, cow, rat, chicken and fish. Life Sci, 35: 1755-1762 (1984).
12. Nagatsu, H., Mukai, S., Takaki, K. and Uchida, H.: Absroption, distribution and excretion of [14C]fleroxacin in rats and rabbits. Chemotherapy, 38 Sup 2: 100-114 (1990).
13. 18F]fleroxacin in healthy human subjects studied by using positron emission tomography. Antimicrob Agents Chemother., 37: 2144-2152 (1993).
14. Bergogne-Berezin, E.: Clinical role of protein binding of quinolones. Clin. Pharmacokinet., 41: 741-750 (2002).
15. Verbeeck, R. K., Blackburn, J. L. and Loewen, G. R.: Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin. Pharmacokinet., 8: 297-331 (1983).
16. Aoki, H., Okazaki, O. and Hakusui, H.: The Pharmacokinetics of DR-3355: absroption, distribution and excretion after oral administration to rats. Yakubutudoutai, 6: 1805-1815 (1991).
17. Grace, R. F., Edwards, S. R.,Mather, L. E., Lin, Y. and Power, I.: Central and peripheral tissue distribution of diclofenac after subcutaneous injection on the rat. Inflammopharmacology, 8: 43-54 (2000).
18. 14C]T-3262 in rats and mice. Jpn. J. Antbiot., 47: 854-866 (1989).
19. 14C]NY-198 in rats and dogs. Chemotherapy, 36: 151 (1988).
20. Okuyama, Y., Momota, K. and Morino, A.: Pharmacokinetics of prulifloxacin, 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Arzneimittelforschung, 47: 276-284 (1997).
21. Sankyo: Interview form of Loxonin®. Tokyo (2001).
22. Gonzalez, M. A., Uribe, F., Moisen, S. D., Fuster, A. P., Selen, A., Welling, P. G. and Painter, B.: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob, Agents Chemother., 26: 741-744 (1984).
23. Yamaguchi, T., Suzuki, R. and Sekine, Y.: Pharmacokinetics of new antibacterial agent AT-2266: plasma levels and urinary excretion of AT-2266 and its metabolites in man. Chemotherapy, 32: 109-116 (1984).
24. Nakashima, M., Uematsu, T., Takiguchi, Y., Mizuno, A. and Itaya, T.: Phase I study of Fleroxacin. Jpn. J. Chemother., 38 Suppl 2: S158-S180 (1990).
25. Nakashima, M., Uematsu, T., Kosuge, K., Kusajima, H., Ooie, T., Ishida, R. and Uchida, H.: Phase I study of gatifloxacin, a new quinolone II; Multiple-dose study. Jpn. J. Chemother., 47 Suppl: S208-S217 (1999a)
26. -)-ofloxacin. Jpn. J. Clin. Pharmacol. Ther., 23: 151-120 (1992).
27. Takahashi, S., Nagayama, Y., Tsujino, D., Naito, S., Someya, K., Yamada, H., Oguma, T. and Shimamura, K.: Pharmacokinetics of NY-198. Jpn. J. Chemother., 36: 240-250 (1988).
28. Sawada, Y. and Ohtani, H.: Pharmacokinetics ABC in clinical fields. The Pharmaceuticals Monthly, 44: 547-564 (2002).
29. Ichihara, N., Tachizawa, H., Tsumura, M., Une, T. and Sato, K.: Phase I study on DL-8280. Jpn. J. Chemother., 32: 118-149 (1984).
30. Nakashima, M., Uematsu, T., Kosuge, K. and Uematsu, T.: Phase I clinical study of pazufloxacin mesilate. Jpn. J. Chemother., 47 Suppl: S141 (1999b).
31. Nakashima, M., Uematsu, T and Kosuge, K.: Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. Jpn. J. Chemother., 44: 180-206 (1996).
32. Sakashita, M., Yokogawa, M., Yamaguchi, T. and Sekine, Y.: Pharmacokinetics of Sparfloxacin in Man. Drug Metab. Pharmacokinet., 6: 43-51 (1991).
33. Nakashima, M., Uematsu, T., Kanamaru, M., Yashuda, T., Watanabe, Y. and Tai, K.: Phase I study of T-3262. Jpn. J. Chemother., 36: 158-180 (1988).
34. Norvatis Pharma: Interview form of Voltaren®. Tokyo.
35. Azuma, J., Harada, H., Ihara, Y., Tsuji, S., Seto, Y., Ogura, M., Noda, K. and Mizushima, Y.: Phase I clinical study of TS-110 (Lornoxicam). Clinical Reports, 30: 2603-2616 (1996).
36. Sasaki, K., Iizuka, K. and Sano, H.: Pharmacokinetics of CN-100 for 80 mg tablet of final preparation in healthy volunteers. Jpn. J. Clin. Pharmacol. Ther., 20: 103-110 (1992).
37. 14C]gatifloxacin after oral administration in rats. Jpn. J. Chemother., 47: 141-146 (1999).
38. 14C-pazufloxacin mesilate in rats and mice. Jpn. J. Chemother., 47: 88-103 (1999).
39. 14C]sparfloxacin in rats. Arzneimittelforschung, 41: 747-759 (1991).
40. Urano, H., Itoga, H., Fukushima, K., Esumi, Y., JIn, Y. and Katami, Y.: Disposition of Lornoxicam. Clinical Reports, 31: 1401-1413 (1997).
41. Haruki, S. and Yamada, A.: Absorption, Distribution, Metabolism and Excretion of CN-100, (±)-2-(10,11-dihydro-10-oxodibenzo [b, f] thiepin-2-yl). Jpn. Pharmacology and Therapeutics, 18: 95-115 (1990).